• Eisai Co Ltd and Biogen Inc on Tuesday said their experimental Alzheimer’s drug significantly slowed the cognitive and functional decline in a large trial of patients.
• The drug, lecanemab, slowed the progress of the brain-wasting disease by 27% compared with a placebo, meeting the study’s primary goal and potentially offering hope for patients.
• The race to stem the progression of Alzheimer’s comes as the number of Americans living with the disease is expected to roughly double to 13 million by 2050, according to the Alzheimer’s Association.

Tagged: Health & Wellness